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Introduction: The properties of a tumor itself were considered the main factors determining the survival of patients
with locally recurrent nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy (IMRT). However,
recurrent tumors were mainly evaluated by using the American Joint Committee on Cancer staging system, which was
modeled on primary tumors and did not incorporate the tumor volume. This study aimed to investigate the prognostic
values of the primary tumor location and tumor volume, and to determine whether evaluating these parameters could
improve the current staging system.
Methods: Magnetic resonance (MR) images for 229 patients with locally recurrent NPC who underwent IMRT were
analyzed retrospectively.
Results: The skull base, parapharyngeal space, and intracranial cavity were the most common sites of tumors. There
was a difference in the survival between patients with T1 and T2 diseases (77.6 % vs. 50.0 %, P < 0.01) and those with
T3 and T4 diseases (33.0 % vs. 18.0 %, P = 0.04) but no difference between patients with T2 and T3 diseases (50.0 % vs.
33.0 %, P = 0.18). Patients with a tumor volume ≤38 cm3 had a significantly higher survival rate compared with those
with a tumor volume >38 cm3 (48.7 % vs. 15.2 %, P < 0.01).
Conclusions: A new staging system has been proposed, with T3 tumors being down-staged to T2 and with the tumor
volume being incorporated into the staging, which may lead to an improved evaluation of these tumors. This new system
can be used to guide the treatment strategy for different risk groups of recurrent NPC.
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Local control for nasopharyngeal carcinoma (NPC) has
greatly improved with the development of radiotherapy
and combined modality treatment; however, local recur-
rence still develops in patients with advanced-stage dis-
eases [1–3]. Imaging plays an important role in
detecting recurrence and becomes the only effective
method of detection when the lesion is deeply seated.
Compared with computed tomography (CT), magnetic
resonance imaging (MRI) has better soft tissue contrast
resolution and is superior in the determination of tumor* Correspondence: hanfei@sysucc.org.cn
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creativecommons.org/publicdomain/zero/1.0/boundaries. Moreover, MRI is a valuable method for dis-
tinguishing a recurrence from fibrosis caused by radi-
ation [3–5].
NPC has a highly infiltrative nature, and as such, most
recurrent cases are advanced. External beam radiation
therapy is becoming the mainstay of treatment for recur-
rent NPC. However, compared with that of patients with
primary tumors, the survival of patients with locally recur-
rent NPC after conventional radiotherapy is poor, owing
to the decreased sensitivity to radiation and severe late
complications [6–8]. Intensity-modulated radiotherapy
(IMRT) targets the tumor site more effectively while min-
imizing the damage to adjacent organs and may improve
the clinical outcome of patients with locally recurrent
NPC [9–11]. Studies have shown that the properties of
the tumor itself are the main factors determining thele distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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practice, recurrent tumors are mainly evaluated according
to the American Joint Committee on Cancer (AJCC) sta-
ging system; however, this system has several limitations.
First, the current staging system was modeled on primary
tumors, but recurrent NPCs differ in their natural behav-
ior and therapeutic requirements. Second, the tumor vol-
ume has proven to be an important prognostic factor in
recent research; however, it has not yet been incorporated
into the staging system.
To address these issues, we assembled a large dataset
from patients with locally recurrent NPC treated with
IMRT and investigated the impact of the tumor sites and
tumor volume on the survival by analyzing MRI. This study
will allow for a more comprehensive evaluation of these tu-
mors, which can, in turn, be used in guiding the treatment
strategy for different risk groups of recurrent NPC.Patients and methods
Patient selection
Between January 2001 and December 2008, 251 patients
were diagnosed with locally recurrent NPC and under-
went re-irradiation using IMRT in Sun Yat-sen Univer-
sity Cancer Center. A total of 229 patients were included
in the study; the remaining 22 patients were excluded
from the study, of which 19 had incomplete MRI infor-
mation and 3 had distant metastasis prior to treatment.
All participants provided written informed consent. Our
protocol was approved by the institutional ethics com-
mittee of Sun Yat-sen University Cancer Center.
All 229 patients underwent MRI of the nasopharynx to
evaluate the local tumor; chest X-ray examinations, sonog-
raphy of the abdomen, and whole-body isotope bone
scans were also carried out to detect any distant metasta-
sis. Positron emission tomography-computed tomography
(PET-CT) was also performed in 34 patients.MRI and the assessment of tumor sites
MRI examinations were performed by using a 1.5-T unit
scanner (General Electric Medical Systems, Fairfield, CT,
USA) with a combined head and neck coil. The following
sequences were obtained before injecting the contrast
material: T1-weighted images in the axial, coronal, and
sagittal planes (repetition time, 500–600 ms; echo time,
10–20 ms) and T2-weighted images in the axial plane
(repetition time, 4,000–6,000 ms; echo time, 95–110 ms).
After a bolus injection of gadopentate dimeglumine (Gd-
DTPA), contrast-enhanced T1-weighted images in the
axial and sagittal planes and T1-weighted fat-suppressed
coronal images were obtained.
Two radiologists specializing in head and neck cancers
evaluated the MR images independently and graded tu-
mors according to the 2009 AJCC staging system. Anydisagreements were resolved by consensus according to
the discussion of the team.
IMRT and the measurement of tumor volume
All patients received a full course of IMRT. The target vol-
umes were set according to the International Commission
on Radiation Units and Measurements. A radiation on-
cologist manually outlined the gross tumor volume in the
nasopharynx (GTV-nx) slice-by-slice on the pretreatment
contrast-enhanced CT images in the planning system ac-
cording to the MRI results. The tumor volume, equal to
GTV-nx, was calculated by using the Corvus inverse
IMRT planning system (version 3.0; Peacock 3.0, Nomos
Corp, Sewickley, PA, USA) with the summation-of-area
technique, which multiplies the area by the image recon-
struction interval of 3 mm. The clinical target volumes
(CTV) were designed to encompass the tumor (including
the GTV) plus a 1.0- to 1.5-cm margin and a further small
margin (<3 mm) where the tumor was in close proximity
to critical intracranial structures or the spinal cord. An
additional 2- to 3-mm margin was added to the CTV to
create the planning target volume (PTV), allowing for
setup variability and internal motion. The prescribed dose
was 60–70 Gy to the GTV-nx and 50–54 Gy to the CTV,
in 27–35 fractions. Treatment was delivered once daily,
over 5 fractions per week. Cisplatin-based induction or
concurrent chemotherapy was administered to 122 pa-
tients with recurrent T3–4 (rT3–4) and/or bulky gross tu-
mors, including concurrent chemoradiotherapy to 46
patients, induction chemotherapy followed by radiother-
apy to 63 patients, and induction and concurrent chemo-
therapy to 13 patients. The concurrent chemotherapy
scheme was mainly cisplatin alone (80–100 mg/m2 intra-
venously every 21 days). The induction chemotherapy reg-
imens included cisplatin (80–100 mg/m2 intravenously
every 21 days) plus 5-fluorouracil (500 mg/m2 intraven-
ously on days 1–5, every 21 days), and/or plus paclitaxel
(175 mg/m2 intravenously every 21 days).
Follow-up and statistical analysis
The duration of follow-up was calculated from the com-
pletion of IMRT to either the day of death or the date of
the last examination. Patients were evaluated at least once
every 3 months during the first 3 years and every 6 months
thereafter until death. Severe late radiation-induced toxic-
ities were recorded.
Receiver operating characteristic (ROC) curves were
drawn to identify the cut-off point and test the prognostic
validity of the tumor volume. The overall survival (OS),
local failure–free survival (LFFS), and distant failure–free
survival (DFFS) were calculated by using the Kaplan-
Meier method, and the difference in survival curves was
compared by using the log-rank test. The categorical vari-
ables, including the complications, were compared with
Table 1 The frequency and the sites of tumor invasion
identified by magnetic resonance imaging in 229 patients with
nasopharyngeal carcinoma (NPC)
Anatomical site No. of patients (%)
Skull base involvement 162 (70.7)
Clivus 140 (61.1)
Basis of sphenoid bone 135 (59.0)
Petrous apex 120 (52.4)
Pterygoid process 114 (49.7)
Foramen lacerum 91 (40.0)
Great wing of sphenoid bone 59 (25.8)
Paranasal sinus 45 (19.7)
Foramen ovale 32 (13.9)
Pterygopalatine fossa 30 (13.1)
Jugular foramen 21 (9.7)
Hypoglossal canal 15 (6.5)
External auditory canal 6 (2.6)
Soft tissue involvement 147 (64.2)
Parapharyngeal space 114 (49.8)
Oropharynx 27 (11.8)
Nasal cavity 23 (10.4)
Prevertebral muscle 21 (9.2)
Masticator space 18 (7.9)
Intracranial invasion 74 (32.3)
Cavernous sinus 71 (31.0)
Retroclival space 11 (4.8)
Orbital apex 11 (4.8)
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and P values were based on two-sided tests.
Results
Patient characteristics
The patient cohort included 176 males and 53 females;
the median age was 46 years (range, 21–79 years). The
median interval from the end of primary radiotherapy to
recurrence was 25 months (range, 6–248 months). Pa-
tients were diagnosed with local recurrence of NPC based
on a biopsy (192 patients) or their clinical symptoms,
signs, and imaging findings in cases of deep-seated lesions
(37 patients). Using the 2009 AJCC staging system, the
numbers of patients with stages I, II, III, and IVa diseases
were 29, 28, 78, and 94, respectively. The majority of pa-
tients in the cohort (75.1 %) had advanced disease (stage
III or IV).
Tumor sites identified by MRI
The frequency and location of tumor invasion sites iden-
tified by MRI are shown in Table 1. The most common
tumor sites were the skull base (70.4 %; Fig. 1a), the
parapharyngeal space (49.8 %; Fig. 1b), and the intracra-
nial cavity (32.3 %; Fig. 1c). The tumor invasion routes
to the cavernous sinus were via the foramen lacerum in
23 patients (32.4 %), via the foramen ovale in 19 patients
(26.7 %), direct invasions via the clivus or sphenoid sinus
in 12 patients (16.9 %), and via at least two of the afore-
mentioned routes in 17 patients (23.9 %).
Treatment outcome
The median follow-up time was 30 months (range, 5–147
months); 12 patients were lost to follow-up after 6 to
36 months (recorded as censored data). Forty-six patients
(20.1 %) developed local failure and 28 (12.2 %) developed
distant metastasis. The 5-year LFFS and DFFS rates were
70.8 % and 84.1 %, respectively.
A total of 155 patients in the cohort died, 71 of whom
(45.8 %) died of radiation-induced injuries, 39 (25.2 %)
died of local failures, 28 (18.0 %) died of distant failures,
and 17 (11.0 %) died of unrelated causes. Of the 71
radiation-induced injuries, 36 were mucosa necrosis or
massive hemorrhage, 13 were radiation-induced tem-
poral lobe necrosis, and 22 were other radiation-related
injuries. The 5-year OS rate was 36.6 %.
Complications
Most patients (85.9 %) developed mild to moderate
acute toxicities while undergoing IMRT, and no patients
had to stop the treatment. After completing IMRT, the
following complications were observed: mucosal necrosis
(77 of 229, 33.6 %; Fig. 2), temporal lobe necrosis (50 of
229, 21.8 %), massive hemorrhage (42 of 229, 18.3 %),
and cranial neuropathy (28 of 229, 12.2 %). There was asignificantly higher incidence of mucosal necrosis in pa-
tients with a tumor volume >38 cm3 compared with
those with a tumor volume ≤38 cm3 (41.3 % vs. 27.2 %,
P = 0.02). The tumor stage was also an independent fac-
tor predicting mucosal necrosis, with an incidence of
13.8 % in rT1, 32.1 % in rT2–3, and 41.5 % in rT4 cases
(P = 0.04).
Analysis of tumor sites and volume as prognostic factors
Based on the invasion sites, recurrent tumors were evalu-
ated according to the 2009 AJCC staging system. The 5-
year OS rates for patients with T1, T2, T3, and T4 tumors
were 77.6 %, 50.0 %, 33.0 %, and 18.0 %, respectively. The
survival rates were significantly different between the pa-
tients with T1 and T2 tumors (P < 0.01) and between
those with T3 and T4 tumors (P = 0.04). However, the dif-
ference in survival rates between the patients with T2 and
T3 tumors was not significant (P = 0.18; Fig. 3a).
The median tumor volume was 37.0 cm3 in the whole
cohort; 11.4 cm3 (1.1–23.0 cm3) for T1 tumors, 25.4 cm3
Fig. 1 Magnetic resonance imaging findings of the common tumor invasion sites in patients with nasopharyngeal carcinoma (NPC). a, the skull
base, the most common tumor invasion site (70.4 %); b, the parapharyngeal space (49.8 %); c, the intracranial cavity (32.3 %). The numbers in the
pictures represent the order of incidence of tumor invasion
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for T3 tumors, and 47.5 cm3 (8.7–146.4 cm3) for T4 tu-
mors. The ROC curves showed that the cut-off value of
tumor volume for the OS was 38.0 cm3. There was a sig-
nificant difference in the survival rates between patients
with a tumor volume ≤38 cm3 and patients with a tumor
volume >38 cm3 (LFFS rate: 72.9 % vs. 56.9 %, P < 0.01;Fig. 2 An NPC patient who developed severe mucosal and skull base
necrosis after re-irradiation. The necrosis, indicating by the arrow, is near
the internal carotid artery (ICA), an area more prone to developing
massive hemorrhageOS rate: 48.7 % vs. 15.2 %, P < 0.01, as shown in Fig. 3b).
The tumor volume was also a prognostic factor for classify-
ing patients with the same Tcategory in a stratified analysis.
The 5-year OS rates for patients with T2, T3, and T4 dis-
ease with a tumor volume ≤38 cm3 were 57.1 %, 39.7 %,
and 19.1 %, respectively, whereas in patients with a tumor
volume >38 cm3, these values were 28.6 % (P = 0.04),
19.1 % (P = 0.02), and 11.4 % (P = 0.01), respectively (Fig. 4).
The site(s) of tumor invasion and the tumor volume
were therefore incorporated into a proposed new staging
system for recurrent NPC (indicated by * in Table 2).
Two revisions were made to the AJCC staging system
based on the survival rates observed in this study: (1) T3
tumors were down-graded to T2, and both T2 and T3
categories were combined into T2*; and (2) all tumors
with a volume >38 cm3 were classified into a high-risk
group renamed T3*. The 5-year OS rates for the T1*,
T2*, and T3* groups were 77.6 %, 45.5 %, and 18.8 %, re-
spectively (P < 0.01; Fig. 3c). The OS curves for these
groups were distinctly separated from each other. ROC
curves were used to compare the prognostic value of in-
corporating the tumor volume into the T staging system.
The area under the curve (AUC) was 0.65 for the T cat-
egory alone, 0.62 for the tumor volume alone, and 0.69
for a combination of the two, indicating that the com-
bination of the tumor sites and volume was superior to
the T category alone (Fig. 3d).
Discussion
In this retrospective study, MRI was used to evaluate the
tumor size and location in patients with recurrent NPC,
providing an accurate evaluation of tumor boundaries.
Fig. 3 Survival curves for NPC patients with different factors. a, patients with the recurrent T category determined according to the American Joint
Committee on Cancer (AJCC) staging system; b, patients stratified by the tumor volume; c, patients with the recurrent T category determined according
to the proposed staging system (Tn*); d, receiver operator characteristic (ROC) curves for the recurrent T category alone, the tumor volume alone, and
the addition of the tumor volume to the recurrent T category in the proposed staging system
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IMRT because it allows the specific targeting of tumor
sites while sparing the surrounding tissues.
The skull base was demonstrated to be the most com-
mon site of extra-nasopharyngeal tumor invasion. This
finding may be related to the propensity of the tumor
for infiltration and the use of MRI, which is superior to
CT scanning, in detecting minimal skull base invasion
[12–14]. Consistent with the results of Chen et al. [14],
we found no significant difference in the survival rates
between patients with skull base invasion and those with
T2 disease. This result could be due to the accuracy of
MRI in detecting minimal bone marrow infiltration,
leading to T category changes, or due to the use of
IMRT, a treatment by which a more precise and higher
radiation dose can be delivered specifically to the tumor
to significantly improve local control. Furthermore, it
was not always possible to distinguish minimal bone
marrow infiltration from radiation-related changes,
which led to difficulty in differentiating some cases of
T3 disease from T2 disease. Therefore, it seemed appro-
priate to down-stage T3 to T2 and to combine them asT2* category; this strategy has also been recommended
for primary NPC [15].
Intracranial invasion, including that of the cavernous
sinus and retroclival space, was common in patients with
recurrent NPC in this study. Using MRI with the
contrast-enhanced fat-suppression technique can pro-
vide an accurate understanding of the route of extension
into the intracranial cavity. We found that most recur-
rent tumors spread intracranially via the foramen
lacerum and foramen ovale, which is consistent with that
of perineural invasion [16]. Intracranial invasion is con-
sidered a negative prognostic factor because (1) tumors
with intracranial invasion are associated with advanced
and bulky diseases with poor local control [10, 11]; (2)
the incidence of serious late complications, including
mucosa necrosis and temporal lobe necrosis, increases
with the size of the area that receives high-dose re-
irradiation; and (3) these sites have anatomically rich
venous plexuses and are conventionally thought to be
potential routes of distant metastasis [17]. Therefore, the
accurate diagnosis of intracranial invasion is important
for creating an appropriate treatment plan.
Fig. 4 Survival curves for NPC patients with different tumor volumes in recurrent T2–4 groups. a, recurrent T2; b, recurrent T3; c, recurrent T4
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cant prognostic factor for recurrent NPC [10, 11]. How-
ever, the data related to the role of the tumor volume in
the staging system were limited. In this study, the cut-off
point was evaluated by an ROC curve, and tumor vol-
ume (≤38 cm3 vs. >38 cm3) was shown to be an inde-
pendent prognostic factor for OS. Patients with a large
tumor (>38 cm3) were more likely to experience local
failure and mucosal necrosis, which became the main
challenge during re-irradiation using IMRT, and these
patients had a low 5-year OS rate (15.2 %). Furthermore,
the tumor volume was also a valuable factor in discrim-
inating patients with T2–4 disease in the subgroup ana-
lysis. Therefore, we concluded that tumors with a
volume >38 cm3 at any site should be considered part of
the highest risk group (T3*). The incorporation of the
tumor volume into the staging system for recurrentTable 2 Tumor properties of NPC used to define the proposed new
2009 AJCC staging system
T: Tumor in the nasopharynx
T1: Tumor confined to the nasopharynx, nasal cavity, or oropharynx
T2: Tumor with parapharyngeal extension
T3: Tumor that invades bony structures and/or the paranasal sinuses
T4: Tumor with intracranial extension and/or involvement of the cranial nerv
hypopharynx, or orbit
*Used to distinguish the tumor stage in the proposed new system from that in theNPC can further improve the accuracy in predicting the
prognosis and can be used to guide the treatment strat-
egy for different risk groups.
The high incidence of late complications has become
the main challenge for patients with recurrent NPC
treated with IMRT. Mucosal necrosis can seriously affect
the quality of life and lead to massive hemorrhage or
even death. However, treatment can be complicated for
the chronic nonhealing wound due to hypoxia and hypo-
vascularity; these factors may be related to personal tol-
erance and the irradiation dose [18–20]. Temporal lobe
necrosis is another complication that develops in pa-
tients following re-irradiation, and it occurred in 21.8 %
of the patients in this study. To reduce the risk of late
complications, it is critical to give an appropriate dose
and identify the patients who will benefit most from re-
irradiation to improve its therapeutic benefit.staging system
Proposed new staging system
T*: Tumor in the nasopharynx
T1*: As per AJCC T1 and with tumor
volume ≤38 cm3
T2*: As per AJCC T2 and/or T3, and with
tumor volume ≤38 cm3
T3*: As per AJCC T4 and/or all tumors with
a volume >38 cm3
e, infratemporal fossa,
American Joint Committee on Cancer (AJCC) staging system
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In conclusion, we have shown that the tumor location
and volume were identified as independent prognostic
factors for recurrent NPC. The proposed new staging
system may lead to an improved evaluation of these tu-
mors, which can be used to guide the treatment strategy
for different risk groups of recurrent NPC. The proposed
new staging system needs to be further tested and vali-
dated in a larger cohort of patients.
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